Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients

Pediatric Transplantation

Volumn 5, Issue 4, 2001, Pages 297-301

  Vester, U ^a   Kranz, B ^a   Testa, G ^a   Malago M ^a   Beelen, D ^a   Broelsch, C E ^a   Hoyer, P F ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Basiliximab; Children; Efficacy; Graft survival; Immunosuppression; Kidney transplantation

Indexed keywords

CYCLOSPORIN A; CYTOGLOBIN; IMMUNOTECH; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISONE; RECEPTOR BLOCKING AGENT; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CADAVER DONOR; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; PEDIATRIC SURGERY; RECEPTOR BLOCKING; SIDE EFFECT; SURVIVAL RATE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; PREDNISONE; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034939584     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.005004297.x     Document Type: Article

References (14)

1. Renal transplantation in children from 1987-1996: The annual report of the North American Pediatric Renal Transplant Cooperative Study
2. Clinical correlates of chronic rejection in pediatric renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study
3. Disposition of basiliximab, a chimeric IL-2 receptor (CD25) monoclonal antibody, in pediatric renal transplant patients
4. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
5. Reduction of the occurence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
6. Disposition of basiliximab in de novo pediatric renal transplantation
7. Neoral absorption profiling: An evolution in effectiveness
8. Risk factors for vascular thrombosis in pediatric renal transplantation
9. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
10. End stage renal failure in children younger than 6 years: Renal transplantation is the therapy of choice
11. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation
12. Tacrolimus-based immunosuppression in pediatric renal transplantation
13. Analysis of hypertension in children post renal transplantation - A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
14. Screening for basiliximab exposure-response relationships in renal allotransplantation